Voluntary nationwide recall: Methocarbamol (Eugia - March)
Apr. 2024Pharmacy Updates
Eugia US LLC is recalling one lot of Methocarbamol Injection, USP 1000 mg/10 mL (100 mg/mL). Methocarbamol is used for the relief of discomfort from acute, painful musculoskeletal conditions.
This drug is being recalled because white particles were found in one vial during a customer’s inspection. Using an injectable product that contains particulate matter may cause local irritation or swelling. It may also block blood vessels, leading to life-threatening blood clot events.
As of the date of Eugia’s recall announcement, March 28, 2024, there have been no reports of adverse events related to this recall. To see if your medication was recalled, contact your doctor or pharmacy where you received the medication or visit the FDA website below.
If you have an affected lot of Methocarbamol, you should stop using the item and return it to the place of purchase.
To learn more about this recall, you can take one or more of the steps below.
This drug is being recalled because white particles were found in one vial during a customer’s inspection. Using an injectable product that contains particulate matter may cause local irritation or swelling. It may also block blood vessels, leading to life-threatening blood clot events.
As of the date of Eugia’s recall announcement, March 28, 2024, there have been no reports of adverse events related to this recall. To see if your medication was recalled, contact your doctor or pharmacy where you received the medication or visit the FDA website below.
If you have an affected lot of Methocarbamol, you should stop using the item and return it to the place of purchase.
To learn more about this recall, you can take one or more of the steps below.
- Talk to your doctor or pharmacist.
- Call Eugia US LLC at 866-850-2876, option 2. TTY users should call 711. Help is available Monday through Friday from 8 a.m. to 5 p.m. EST.
- Visit the FDA website.
Recent Announcements
HPV Vaccination Resources
To help protect against cancers later in life, it is important to increase HPV vaccination rates in adolescents starting at age 9. According to the Centers for Disease Control and Prevention, HPV vaccination is routinely recommended at age 11 or 12, but the vaccine can be given starting at age 9.1 The Pennsylvania Cancer Coalition cites the following potential benefits of initiating the HPV vaccine series at age 9:2Mar. 2025Important Notices
Special notice: Important policy changes
Effective May 1, 2025, the following policies will be retired and replaced with prior authorization policies. For more information, please visit upmchp.us/policiesandprocedures.Mar. 2025Important Notices
CME Webinar: Essential Best Practices for Newborn Care: Ensuring Healthy Beginnings Through Comprehensive Care
Please join us for a live, CME-accredited webinar on Wednesday, May 7, from noon to 1 p.m. that will provide an overview of newborn care.Feb. 2025Education/Webinars